Oxidative stress is a major pathogenic factor in Alzheimer's disease, but it should not be tackled alone rather together with other key targets to derive effective treatments. The combination of the scaffold of the polar antioxidant lead 7-methoxy-2,2-dimethylchroman-6-ol (CR-6) with that of the lipophilic cholinesterase inhibitor 6-chlorotacrine results in compounds with favorable brain permeability and multiple activities in vitro (acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE-1), and Aβ42 and tau aggregation inhibition). In in vivo studies on wild-type and APP/presenilin 1 (PS1) mice, two selected compounds were well tolerated and led to positive trends, albeit statistically nonsignificant in some cases, on memory performance, amyloid pathology (reduced amyloid burden and potentiated non-amyloidogenic APP processing), and oxidative stress (reduced cortical oxidized proteins and increased antioxidant enzymes superoxide dismutase 2 (SOD2), catalase, glutathione peroxidase 1 (GPX1), and heme oxygenase 1 (Hmox1) and transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2)). These compounds emerge as interesting brain-permeable multitarget compounds, with a potential as anti-Alzheimer agents beyond that of the original lead CR-6.

Pérez-Areales, F.J., Garrido, M., Aso, E., Bartolini, M., De Simone, A., Espargaró, A., et al. (2020). Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. JOURNAL OF MEDICINAL CHEMISTRY, 63(17), 9360-9390 [10.1021/acs.jmedchem.0c00528].

Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6

Bartolini, Manuela
Methodology
;
Andrisano, Vincenza;
2020

Abstract

Oxidative stress is a major pathogenic factor in Alzheimer's disease, but it should not be tackled alone rather together with other key targets to derive effective treatments. The combination of the scaffold of the polar antioxidant lead 7-methoxy-2,2-dimethylchroman-6-ol (CR-6) with that of the lipophilic cholinesterase inhibitor 6-chlorotacrine results in compounds with favorable brain permeability and multiple activities in vitro (acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE-1), and Aβ42 and tau aggregation inhibition). In in vivo studies on wild-type and APP/presenilin 1 (PS1) mice, two selected compounds were well tolerated and led to positive trends, albeit statistically nonsignificant in some cases, on memory performance, amyloid pathology (reduced amyloid burden and potentiated non-amyloidogenic APP processing), and oxidative stress (reduced cortical oxidized proteins and increased antioxidant enzymes superoxide dismutase 2 (SOD2), catalase, glutathione peroxidase 1 (GPX1), and heme oxygenase 1 (Hmox1) and transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2)). These compounds emerge as interesting brain-permeable multitarget compounds, with a potential as anti-Alzheimer agents beyond that of the original lead CR-6.
2020
Pérez-Areales, F.J., Garrido, M., Aso, E., Bartolini, M., De Simone, A., Espargaró, A., et al. (2020). Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. JOURNAL OF MEDICINAL CHEMISTRY, 63(17), 9360-9390 [10.1021/acs.jmedchem.0c00528].
Pérez-Areales, F Javier; Garrido, María; Aso, Ester; Bartolini, Manuela; De Simone, Angela; Espargaró, Alba; Ginex, Tiziana; Sabate, Raimon; Pérez, Be...espandi
File in questo prodotto:
File Dimensione Formato  
jm0c00528_si_001.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 6.06 MB
Formato Adobe PDF
6.06 MB Adobe PDF Visualizza/Apri
jm0c00528_si_002.xls

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 26 kB
Formato Microsoft Excel
26 kB Microsoft Excel Visualizza/Apri
Revised Text_MunozTorrero.pdf

Open Access dal 25/07/2021

Descrizione: accepted manuscript
Tipo: Postprint
Licenza: Licenza per accesso libero gratuito
Dimensione 1.39 MB
Formato Adobe PDF
1.39 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/789864
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 28
social impact